A 42-year-old woman recently diagnosed with rheumatoid arthritis asks the nurse practitioner about disease-modifying antirheumatic drugs (DMARDs). Which of the following statements about DMARDs is INCORRECT?

Choice A reason: DMARDs are designed to address the underlying autoimmune inflammation driving rheumatoid arthritis, not just symptomatic relief. Choice B reason: By reducing inflammation, DMARDs limit joint damage and improve physical function over time. Choice C reason: DMARDs comprise several classes, including conventional synthetic, biologic, and targeted synthetic DMARDs, and can be administered orally, subcutaneously, or intravenously. Choice D reason: Symptom improvement with DMARDs typically takes several weeks to months, often 6-12 weeks, rather than 3 weeks, making this statement inaccurate.